Cancer antigen 15-3 (CA 15-3) is a protein found in the blood that is primarily used to monitor breast cancer treatment and detect recurrence. It comes from a larger protein called MUC1, which sits on the surface of many cells throughout the body. In healthy tissue, MUC1 plays a protective role. But when cancer develops, cells produce abnormal versions of this protein that break off and enter the bloodstream, where they can be measured with a simple blood draw.
The standard upper limit for CA 15-3 is 25 U/mL. Levels above that threshold are considered elevated, though an elevated result alone does not confirm cancer.
How CA 15-3 Is Used in Breast Cancer Care
CA 15-3 is most valuable as a monitoring tool, not a diagnostic one. It is commonly ordered for people already diagnosed with breast cancer, particularly those with advanced or metastatic disease. A steady rise in CA 15-3 over time is a reliable indicator of disease progression or recurrence. Conversely, falling levels during chemotherapy or other treatment generally signal that the cancer is responding.
The test is especially useful for catching distant metastases early. Research from the National Federation of French Cancer Centers found that CA 15-3 is effective at flagging cancer that has spread to distant organs like the bones, liver, or lungs, though it performs poorly for detecting local recurrence near the original tumor site. This means a normal CA 15-3 level doesn’t guarantee the cancer hasn’t come back locally, but a rising level is a strong prompt for further imaging.
Interestingly, the American Society of Clinical Oncology does not formally recommend using CA 15-3 for routine surveillance after primary breast cancer treatment. Despite this, many oncologists order it regularly because the test is fast, inexpensive, noninvasive, and easy to repeat over time. ASCO does recognize CA 15-3 as having clinical utility in certain contexts, particularly for monitoring treatment response in metastatic disease.
What the Numbers Mean
Most labs set the normal reference range at below 25 U/mL. But a single number in isolation tells you very little. What matters far more is the trend: how your levels change over weeks and months. A result of 28 U/mL that has been stable for a year means something very different from a result of 28 U/mL that was 18 U/mL three months ago.
Some research suggests that using a lower cutoff of around 19 U/mL improves the test’s ability to detect active disease, yielding about 70% sensitivity and 90% specificity. At the standard cutoff of 30 U/mL, the test misses more cases but produces fewer false alarms. Your oncologist will interpret your results in the context of your specific history and clinical picture rather than relying on a single fixed threshold.
Why It’s Not Used for Screening
CA 15-3 is not recommended as a screening test for breast cancer in the general population. The reason is straightforward: its sensitivity hovers around 65 to 70%, meaning it misses roughly a third of people who do have active disease. A negative result cannot safely rule out cancer, and a positive result doesn’t confirm it. For early-stage breast cancer in particular, CA 15-3 levels are often completely normal, making the test unreliable for catching the disease before it progresses.
Patients with marker levels below clinical cutoffs still need standard surveillance, including imaging. The test is a complement to other tools, never a replacement.
Non-Cancer Causes of Elevated Levels
An elevated CA 15-3 result does not automatically mean cancer. Several benign conditions can push levels above the normal range, including:
- Benign breast disease or benign ovarian disease
- Endometriosis
- Pelvic inflammatory disease
- Hepatitis and other liver conditions
- Pregnancy and breastfeeding
Beyond breast cancer, elevated CA 15-3 can also appear in cancers of the ovary, lung, and prostate. This overlap is another reason the test works best as a monitoring tool within an established diagnosis rather than as a standalone diagnostic.
CA 15-3 Combined With Other Markers
Oncologists often order CA 15-3 alongside another blood marker called CEA (carcinoembryonic antigen) to improve accuracy. A retrospective study of 743 breast cancer patients found that CA 15-3 alone detected metastatic recurrence with about 56% sensitivity, while CEA alone caught about 41%. When both markers were used together, sensitivity climbed to roughly 66 to 71%, depending on whether doctors used fixed cutoff values or tracked each patient’s individual baseline over time.
Tracking how your own levels change from one blood draw to the next, rather than comparing against a universal cutoff, produces the most reliable results. This personalized approach significantly improves both the ability to catch real recurrences and the ability to avoid false alarms.
CA 15-3 vs. CA 27.29
You may also encounter a related test called CA 27.29. Both markers come from the same MUC1 protein but are detected by different laboratory methods. A comparison study found that CA 27.29 actually discriminates between breast cancer patients and healthy individuals better than CA 15-3, particularly in early-stage disease. CA 27.29 had a positivity rate of about 35% in breast cancer patients compared to 23% for CA 15-3. In practice, most oncologists use one or the other (not both), and the choice often depends on what the local lab offers.
What the Blood Test Involves
The CA 15-3 test is a standard blood draw with one preparation step: you should avoid multivitamins or dietary supplements containing biotin (vitamin B7) for 12 hours before the test. This includes many hair, skin, and nail supplements, which tend to contain high doses of biotin. Biotin can interfere with the laboratory assay and produce inaccurate results.
No other fasting is required. Results are typically available within a few days, and your doctor will compare them against your previous results to assess the trend rather than interpreting any single number in isolation.